Abstract: The present invention relates to an antibody specifically binding to apoptosis inhibitor 5 (API5) protein and uses thereof. The antibody or antigen-binding fragment thereof that specifically binds to API5 according to the present invention can have excellent anticancer effects, such as inhibiting phosphorylation of ERK in cancer cells and inhibiting cancer growth. In addition, the antibody or antigen-binding fragment thereof exhibits excellent anticancer effects against cancers that are resistant or refractory to anticancer drugs. Accordingly, it is useful for preventing or treating cancers resistant or refractory to anticancer drugs as well as general cancers.

Abstract: The present invention relates to an antibody specifically binding to apoptosis inhibitor 5 (API5) protein and uses thereof. The antibody or antigen-binding fragment thereof that specifically binds to APIS according to the present invention can have excellent anticancer effects, such as inhibiting phosphorylation of ERK in cancer cells and inhibiting cancer growth. In addition, the antibody or antigen-binding fragment thereof exhibits excellent anticancer effects against cancers that are resistant or refractory to anticancer drugs. Accordingly, it is useful for preventing or treating cancers resistant or refractory to anticancer drugs as well as general cancers.

Abstract: The present disclosure relates to the ssRNA-specific ribonuclease activity of SAMHD1 (sterile alpha motif (SAM) domain and HD domain-containing protein 1) and its use. It is noteworthy that SAMHD1 has dual catalytic functions which are ribonuclease activity and dNTPase activity: however unlike the dNTPase activity, the ribonuclease activity of SAMHD1 did not require the cofactor dGTP. The present invention can be employed to degrade viral genomic ssRNA and to prevent or treat a ssRNA viral infection.